Rebuilding Brain Connections for Parkinson's Disease
Tissue Engineered Nigrostriatal Pathway for Anatomical Tract Reconstruction in Parkinson's Disease
This work explores a new way to replace lost brain cells and their connections in Parkinson's disease using specially grown tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11160471 on NIH RePORTER |
What this research studies
Parkinson's disease causes motor symptoms because specific brain cells that produce dopamine are lost, along with their long connections to another brain area. Current cell therapies often place new cells in the target area but don't rebuild these crucial connections. This approach aims to create a complete 'pathway' of human stem cell-derived dopamine neurons and their connections within a protective gel. These engineered pathways could then be implanted to restore both the neurons and their vital connections, potentially improving brain circuit function.
Who could benefit from this research
Good fit: This foundational work in animal models is for patients with Parkinson's disease who might benefit from future therapies that rebuild brain pathways.
Not a fit: Patients seeking immediate treatment or direct participation in human clinical trials would not benefit from this early-stage animal model research.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatments for Parkinson's disease by restoring the brain's natural connections, potentially improving motor function more significantly than current cell therapies.
How similar studies have performed: While conventional cell therapies for Parkinson's have been explored, this specific strategy of tissue-engineered pathway reconstruction is a novel and largely untested approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cullen, Daniel Kacy — University of Pennsylvania
- Study coordinator: Cullen, Daniel Kacy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.